Cell Source, Inc. (CLCS)
USD 0.5
(0.0%)
USD 0.5
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 9.25 Million USD | 17.08% |
| 2022 | 7.9 Million USD | 22.18% |
| 2021 | 6.46 Million USD | 34.61% |
| 2020 | 4.8 Million USD | 84.96% |
| 2019 | 2.59 Million USD | -2.8% |
| 2018 | 2.67 Million USD | 15.16% |
| 2017 | 2.32 Million USD | -24.83% |
| 2016 | 3.08 Million USD | 143.88% |
| 2015 | 1.26 Million USD | 1166.15% |
| 2014 | 100 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 9.3 Million USD | 0.5% |
| 2024 Q2 | 10 Million USD | 7.6% |
| 2023 Q4 | 9.25 Million USD | -2.32% |
| 2023 Q2 | 9.45 Million USD | 10.39% |
| 2023 Q1 | 8.56 Million USD | 8.37% |
| 2023 Q3 | 9.47 Million USD | 0.19% |
| 2023 FY | 9.25 Million USD | 17.08% |
| 2022 Q2 | 6.2 Million USD | 1.15% |
| 2022 Q3 | 7.18 Million USD | 15.72% |
| 2022 FY | 7.9 Million USD | 22.18% |
| 2022 Q1 | 6.13 Million USD | -5.11% |
| 2022 Q4 | 7.9 Million USD | 10.01% |
| 2021 Q4 | 6.46 Million USD | -7.93% |
| 2021 Q3 | 7.02 Million USD | 2.22% |
| 2021 Q2 | 6.87 Million USD | 18.6% |
| 2021 FY | 6.46 Million USD | 34.61% |
| 2021 Q1 | 5.79 Million USD | 20.59% |
| 2020 Q4 | 4.8 Million USD | 23.86% |
| 2020 Q2 | 3.43 Million USD | 12.26% |
| 2020 Q3 | 3.88 Million USD | 13.02% |
| 2020 FY | 4.8 Million USD | 84.96% |
| 2020 Q1 | 3.05 Million USD | 17.7% |
| 2019 Q2 | 1.98 Million USD | 0.0% |
| 2019 FY | 2.59 Million USD | -2.8% |
| 2019 Q1 | 1.98 Million USD | -25.81% |
| 2019 Q4 | 2.59 Million USD | 24.12% |
| 2019 Q3 | 2.09 Million USD | 5.57% |
| 2018 Q3 | 2.97 Million USD | 0.0% |
| 2018 FY | 2.67 Million USD | 15.16% |
| 2018 Q1 | 2.92 Million USD | 26.15% |
| 2018 Q2 | 2.97 Million USD | 1.54% |
| 2018 Q4 | 2.67 Million USD | -10.09% |
| 2017 FY | 2.32 Million USD | -24.83% |
| 2017 Q1 | 2.39 Million USD | -22.51% |
| 2017 Q2 | 2.42 Million USD | 1.32% |
| 2017 Q3 | 2.42 Million USD | -0.01% |
| 2017 Q4 | 2.32 Million USD | -4.24% |
| 2016 Q2 | 2.56 Million USD | 37.34% |
| 2016 FY | 3.08 Million USD | 143.88% |
| 2016 Q3 | 2.87 Million USD | 12.32% |
| 2016 Q4 | 3.08 Million USD | 7.24% |
| 2016 Q1 | 1.86 Million USD | 47.42% |
| 2015 Q3 | 758.72 Thousand USD | 14.32% |
| 2015 Q2 | 663.7 Thousand USD | 56.09% |
| 2015 Q1 | 425.2 Thousand USD | 325.2% |
| 2015 FY | 1.26 Million USD | 1166.15% |
| 2015 Q4 | 1.26 Million USD | 66.88% |
| 2014 Q4 | 100 Thousand USD | 0.0% |
| 2014 FY | 100 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 77.54% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -124.509% |
| SQZ Biotechnologies Company | 27.47 Million USD | 66.313% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 78.664% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 68.911% |
| Mesoblast Limited | 118.7 Million USD | 92.204% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -875.9% |
| Genus plc | 233.1 Million USD | 96.03% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -215.8% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -588.768% |
| Marizyme, Inc. | 18.71 Million USD | 50.559% |
| ContraFect Corporation | 2.88 Million USD | -221.214% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1133.89% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -6730.304% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -539.843% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -297.866% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -63.549% |
| MultiCell Technologies, Inc. | 202.58 USD | -4568057.765% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 83.903% |
| EV Biologics, Inc. | 1.49 Million USD | -519.111% |
| Q BioMed Inc. | 4.1 Million USD | -125.163% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 72.043% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1368.737% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -653.376% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1158.144% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 94.605% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 28.798% |
| Skye Bioscience, Inc. | 4.61 Million USD | -100.512% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -942.062% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -6439.22% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -57.623% |
| IMV Inc. | 28.88 Million USD | 67.961% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -35881.858% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -309.77% |
| GB Sciences, Inc. | 1.75 Million USD | -426.012% |
| Alpha Cognition Inc. | 1.22 Million USD | -658.308% |
| HST Global, Inc. | 98.31 Thousand USD | -9312.396% |
| CSL Limited | 12.18 Billion USD | 99.924% |
| Halberd Corporation | 150 Thousand USD | -6069.449% |
| Enzolytics Inc. | 996.33 Thousand USD | -828.819% |
| Resverlogix Corp. | 6.49 Million USD | -42.569% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1838.047% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -3520.682% |
| argenx SE | 20 Million USD | 53.729% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 79.688% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -241.646% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -90405.369% |
| Genscript Biotech Corporation | 417.73 Million USD | 97.785% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -4512.879% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -285.957% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3935.995% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 86.319% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -205.803% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2472.676% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 54.476% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -6125.311% |
| BioStem Technologies, Inc. | 4.71 Million USD | -96.42% |
| ONE Bio Corp. | 19.71 Million USD | 53.06% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -3598.977% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -3620.72% |
| Agentix Corp. | 50 Thousand USD | -18408.348% |
| LadRx Corporation | 33.6 Thousand USD | -27437.267% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1123.767% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1123.767% |
| NovAccess Global Inc. | 2.19 Million USD | -320.667% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -30.842% |
| Itoco Inc. | 228.37 Thousand USD | -3952.148% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -4286.384% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -85.715% |
| Kadimastem Ltd | 891.22 Thousand USD | -938.364% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2202.898% |
| CytoDyn Inc. | 30.07 Million USD | 69.231% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1810.898% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -2530.17% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -18.34% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -7454.428% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2885.217% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -95.43% |
| International Stem Cell Corporation | 4.17 Million USD | -121.498% |
| Bioxytran, Inc. | 1.92 Million USD | -380.736% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -14727.318% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -324.328% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -11.282% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -7.795% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -494.94% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -3353.05% |
| Neutra Corp. | 54.15 Thousand USD | -16987.994% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -405.693% |
| PureTech Health plc | 25.51 Million USD | 63.726% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -655.92% |
| IXICO plc | 472.02 Thousand USD | -1860.535% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 40.3% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 85.137% |
| CSL Limited | 12.18 Billion USD | 99.924% |
| Cellectis S.A. | 92.77 Million USD | 90.025% |